{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ARX",
  "name": "Accelerant Holdings",
  "url": "https://frontierpicks.com/dossiers/ARX/",
  "json_url": "https://frontierpicks.com/dossiers/ARX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Signed all-cash take-private at $20.25; the 2026-08-21 close of $19.59 leaves a fixed-price insurance-regulatory arb with the ceiling contractually set. Newly visible merger terms — go-shop ending 2026-09-22, outside date 2027-08-13 auto-extending to 2027-11-13, ticking amount that starts only after all other conditions clear — say the clock can run well past the guided H1 2027 close.",
  "invalidation_trigger": "A daily close below $18.25, a discount to the $20.25 cash consideration far wider than anything held since 2026-08-13, marks repriced completion odds; a termination 8-K, or a proxy relying on the 2027-11-13 extended outside date, would confirm the break.",
  "catalyst_date": "2026-09-22",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Dual-class structure: Class A and Class B both receive $20.25; Altamont holds ~82% of voting rights, so public holders cannot affect the vote outcome.",
    "Conflicted-controller deal: Altamont and the founders intend to roll equity alongside Thoma Bravo; a special committee retained Houlihan Lokey and Conyers Dill & Pearman.",
    "Cayman-law merger with Cherry Tree BidCo (Thoma Bravo Discover Fund V affiliate); the 8-K references excluded and dissenting shares, so statutory appraisal mechanics apply.",
    "The Q2 2026 earnings call was cancelled on 2026-08-13; expect reduced guidance and disclosure cadence while the deal is pending.",
    "Accelerant listed on the NYSE only in 2025, so multi-year public financials and long-run technical structure are limited."
  ],
  "body_markdown": "\n**# ARX — Accelerant Holdings**\n\n## Current Thesis\nNothing about the price has moved since the deal was struck: the 2026-08-14 close was $19.58 and the 2026-08-21 close was $19.59. What has moved is the paperwork. The merger agreement behind the 2026-08-13 announcement is now readable, and it fills in exactly the terms that were missing a week ago — a go-shop period running to 2026-09-22, an outside date of 2027-08-13 that automatically extends to 2027-11-13, a company termination fee of $136.5M ($56.9M if the board accepts a superior proposal from an Excluded Party surfaced in the go-shop), a parent termination fee of $295.8M, and a ticking amount of $0.00333 per share per calendar day.\n\nThe narrative leg an investor buys here is no longer specialty-MGA growth. It is a fixed cash claim of $20.25 per Class A and Class B share (Thoma Bravo press release, 2026-08-13; 49% premium to the 2026-08-12 close; enterprise value above $4 billion), collected on an insurance-regulatory calendar. The 2026-08-21 close of $19.59 sits $0.66 under the stated consideration. Everything else is timing.\n\n**The narrative is saturated.** The entire re-rating occurred in one session — shares rose 44.2% on 2026-08-13 (Benzinga) — and coverage peaked the same week, with William Blair cutting to Market Perform on 2026-08-13 and Citizens on 2026-08-14. There is no mechanism for a marginal bid above the contractual ceiling other than a topping proposal, and the only window designed to produce one closes on 2026-09-22. No filings have appeared on the tape since the announcement 8-Ks.\n\n## Bull Case\n- **The buyer's walk-away cost exceeds the seller's.** Parent termination fee $295.8M against a company fee of $136.5M (merger agreement summary, 2026-08-13). A reverse fee set at more than twice the company fee is a measurable commitment, and the deal carries no financing condition — Thoma Bravo provided an equity commitment (8-K, 2026-08-13).\n- **The shareholder vote is functionally decided.** Altamont Capital Partners entities holding roughly 82% of outstanding voting rights signed support agreements on 2026-08-13. The condition that usually drives take-private spreads is off the board.\n- **Delay in the regulatory tail is priced into the contract.** A ticking amount of $0.00333 per share accrues for each calendar day from the date all closing conditions other than the specified insurance approvals are satisfied, until those approvals are obtained (8-K, 2026-08-13). Waiting on state and international insurance regulators is not free to the buyer.\n- **No operating hook for a material-adverse-change argument.** Q2 2026 revenue of $356.9M against $279.228M consensus, adjusted EPS $0.32 against $0.16 (Benzinga, 2026-08-13), printed the same morning the agreement was signed.\n- **A live, dated path to more than $20.25 exists until 2026-09-22.** The go-shop runs from signing to one minute before 12:00 a.m. ET on 2026-09-22, and a superior proposal from an Excluded Party carries the reduced $56.9M fee. As of 2026-08-23 no competing proposal has been disclosed.\n\n## Bear Case\n- **The compensation clock does not start when the wait starts.** The ticking amount begins only once every other closing condition is satisfied, and its start is pushed back further if the Change of Control Filing is made more than 15 business days after signing (8-K, 2026-08-13). Months spent on the proxy, the 13E-3 and the earlier approvals accrue nothing.\n- **The contract tolerates a far longer wait than the guidance.** Parties guide to a close in the first half of 2027; the agreement's outside date is 2027-08-13, extending automatically to 2027-11-13 if only antitrust and insurance conditions remain. Twelve to fifteen months of contractual runway sits behind a guided window that ends 2027-06-30.\n- **The ceiling is fixed and the escape hatch expires in weeks.** With ~82% of the vote committed to Thoma Bravo and Altamont plus the founders intending to roll equity into the private vehicle, a competing bidder would need the controlling holder's cooperation. The go-shop lapses on 2026-09-22 and a no-shop regime begins.\n- **Break risk is many multiples of the remaining spread.** $20.25 is a 49% premium to the 2026-08-12 close. A termination returns the equity toward a level far below the current close, against $0.66 of gross upside.\n- **Both covering brokers stepped aside within 48 hours.** William Blair on 2026-08-13, Citizens on 2026-08-14, both to Market Perform. Rating-driven demand is gone.\n- **The exit price is below where the stock traded this year.** The 52-week high is $30.05; the cash consideration is $20.25.\n\n## Setup & Price Structure\n- **Deal-pinned, not trending.** One cent separates the 2026-08-14 and 2026-08-21 closes. The three-month price change of +13.6% is entirely the single 2026-08-13 gap; there is no continuation leg.\n- **RSI(14) at 94.5 is mechanical.** A step-function repricing on one session leaves the oscillator extended for weeks regardless of flow. Reading it as momentum misreads the structure.\n- **Distance to the 52-week high of $30.05 (-34.8% from the 2026-08-21 close) is now a historical artifact.** The relevant band runs from a repriced-completion-odds floor up to $20.25 plus accrued ticking amount.\n- **Positioning observables.** Retail-facing coverage clustered on 2026-08-13 and 2026-08-14 (buyout wraps, two downgrades) and has been quiet since. There is no scheduled earnings print in the window — the Q2 2026 call was cancelled on the announcement date. No insider transactions or issuance into the gap have surfaced on the tape as of 2026-08-23. What is left is arb inventory rebuilding against a spread that has not widened.\n- **Where the structure breaks.** Closes drifting toward the high $18s without deal-specific news would say the market is repricing either completion odds or the length of the calendar; a daily close below $18.25 is roughly a 10% discount to $20.25, far wider than anything since 2026-08-13.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-09-04 (est.)** — Change of Control Filing Deadline reference point: the agreement sets a 15-business-day marker from the 2026-08-13 signing, beyond which the ticking amount's start date is pushed out day-for-day. Whether filings go in on schedule is a direct input to holder compensation.\n- **2026-09-22** — Go-shop period ends (one minute prior to 12:00 a.m. ET); no-shop restrictions begin. This is the last dated mechanism through which a price above $20.25 could emerge; if it passes with no Excluded Party named, the ceiling is settled.\n- **~2026-09-30 (est.)** — Preliminary proxy statement / Schedule 13E-3. First full public view of the background of the merger, the special committee's fairness analysis (Houlihan Lokey retained), and the finalised Altamont/founder rollover terms.\n\n## What Would Change Our Mind\nThe cleanest disconfirmation is a go-shop that lapses on 2026-09-22 with no Excluded Party identified and no supplemental disclosure — that removes the only contractual route above $20.25 and reduces the name to a waiting game on insurance regulators, with the compensation clock not yet running. A preliminary proxy that leans on the 2027-11-13 extended outside date, or discloses that the change-of-control filings slipped past the 15-business-day marker, would say the same thing from the other direction: the holding period is longer than the H1 2027 guidance implies and less of it is compensated.\n\nOn price, a daily close below $18.25 — a discount to the $20.25 consideration far outside the band held since 2026-08-13 — would mark repriced completion odds rather than noise. A termination 8-K, or a formal regulatory denial of a change-of-control filing, confirms the break outright. In the other direction, a competing proposal disclosed before 2026-09-22, or a Thoma Bravo price increase, would reopen the upside the current structure closes off.\n\n## Correlation Notes\n- Since 2026-08-13 the shares have decoupled from specialty-insurance and MGA comparables. Peer multiple moves now matter only as a material-adverse-change input, not as a valuation driver.\n- The residual sensitivity is to the sponsor take-private complex: if spreads widen across comparable pending private-equity deals on credit or financing conditions, this one widens with them despite carrying an equity commitment and no financing condition.\n- Insurance-regulatory approval timelines are jurisdiction-specific and largely uncorrelated with equity markets — the dominant risk factor here is not tradable elsewhere.\n- Rate moves affect the discounted value of a fixed $20.25 payable in 2027 and therefore the equilibrium spread, independent of any company news.",
  "first_seen": "2026-08-14",
  "last_analyzed": "2026-08-23T12:04:03+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}